Regulatory affairs plays a critical role in the success of clinical trials, ensuring ethical standards, safeguarding participant consent, and accelerating the research process. In this episode of the Alzheimer’s Research Podcast, Elizabeth Shaffer, Regulatory Affairs Manager at the Alzheimer’s Therapeutic Research Institute (ATRI), joins the conversation to shed light on the complexities of regulatory oversight in Alzheimer’s clinical trials.
Elizabeth delves into the Alzheimer’s Clinical Trials Consortium (ACTC)’s ongoing efforts to refine the consent process and strengthen protections for research participants. She provides an insightful overview of the Institutional Review Board (IRB) system—an essential safeguard ensuring that studies meet ethical and scientific standards.
Throughout her career, Elizabeth has witnessed key advancements in the regulatory landscape, paving the way for faster, more efficient trials. In this episode, she reflects on ATRI’s progress, shares pivotal milestones, and offers her perspective on what’s next for Alzheimer’s research.
Join us for an eye-opening discussion on the intersection of policy, ethics, and innovation in clinical research—because behind every breakthrough, there’s a framework that makes it possible. Listen now!
